scholarly journals Tumour growth delay following single dose irradiation of human melanoma xenografts. Correlations with tumour growth parameters, vascular structure and cellular radiosensitivity

1985 ◽  
Vol 51 (2) ◽  
pp. 201-210 ◽  
Author(s):  
E K Rofstad ◽  
T Brustad
Keyword(s):  
Single Dose ◽  
Tumour Growth ◽  
Growth Parameters ◽  
Human Melanoma ◽  
Growth Delay ◽  
Vascular Structure ◽  
Cellular Radiosensitivity ◽  
Tumour Growth Delay ◽  
Dose Irradiation

scholarly journals Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model

2020 ◽  
Vol 123 (7) ◽  
pp. 1089-1100 ◽  
Author(s):  
Yiannis Philippou ◽  
Hanna T. Sjoberg ◽  
Emma Murphy ◽  
Said Alyacoubi ◽  
Keaton I. Jones ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Flow Cytometry ◽  
T Cell ◽  
Dendritic Cell ◽  
Tumour Growth ◽  
Hypofractionated Radiotherapy ◽  
Growth Delay ◽  
Immune Microenvironment ◽  
Tumour Growth Delay ◽  
Cancer Models

Abstract Background Radiotherapy enhances innate and adaptive anti-tumour immunity. It is unclear whether this effect may be harnessed by combining immunotherapy with radiotherapy fractions used to treat prostate cancer. We investigated tumour immune microenvironment responses of pre-clinical prostate cancer models to radiotherapy. Having defined this landscape, we tested whether radiotherapy-induced tumour growth delay could be enhanced with anti-PD-L1. Methods Hypofractionated radiotherapy was delivered to TRAMP-C1 and MyC-CaP flank allografts. Tumour growth delay, tumour immune microenvironment flow-cytometry, and immune gene expression were analysed. TRAMP-C1 allografts were then treated with 3 × 5 Gy ± anti-PD-L1. Results 3 × 5 Gy caused tumour growth delay in TRAMP-C1 and MyC-CaP. Tumour immune microenvironment changes in TRAMP-C1 at 7 days post-radiotherapy included increased tumour-associated macrophages and dendritic cells and upregulation of PD-1/PD-L1, CD8+ T-cell, dendritic cell, and regulatory T-cell genes. At tumour regrowth post-3 × 5 Gy the tumour immune microenvironment flow-cytometry was similar to control tumours, however CD8+, natural killer and dendritic cell gene transcripts were reduced. PD-L1 inhibition plus 3 × 5 Gy in TRAMP-C1 did not enhance tumour growth delay versus monotherapy. Conclusion 3 × 5 Gy hypofractionated radiotherapy can result in tumour growth delay and immune cell changes in allograft prostate cancer models. Adjuncts beyond immunomodulation may be necessary to improve the radiotherapy-induced anti-tumour response.

Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts

2000 ◽  
Vol 45 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Mark R. Middleton ◽  
Jane Kelly ◽  
Sarah Goodger ◽  
Nicholas Thatcher ◽  
Geoffrey P. Margison
Keyword(s):  
Tumour Growth ◽  
Therapeutic Index ◽  
Growth Delay ◽  
Tumour Growth Delay
Sign in / Sign up

Export Citation Format

Share Document